This episode features Martin Shkreli, American investor and businessman, discussing the current state of AI, hardware innovation, and pharmaceutical development. The conversation covers the competitive dynamics between OpenAI and Anthropic, the future of computing hardware, and opportunities in biotech.

Shkreli shares insights from his experience building financial software, developing FDA-approved drugs, and launching a photonic computing startup. The discussion explores pricing strategies in AI, the technical challenges of optical computing, and why he believes the peptide medicine trend is fundamentally misguided.

The conversation concludes with analysis of SBF's case and potential redemption, drawing from Shkreli's own experience with legal challenges and business comebacks.

OpenAI vs Anthropic: The Revenue Reality Behind AI Competition

OpenAI could dramatically increase revenue by adopting Anthropic's aggressive pricing model, with enterprise customers currently paying 5-7x their allocated usage without complaint

"If OpenAI did the same monetization effort as Anthropic, their real revenue right now would be about 200 versus their 30" - Martin estimates OpenAI's true revenue potential

Dario Amodei's AI safety messaging is characterized as marketing theater: "he tried to scare the world by saying AI is going to kill you... it's kind of the greatest marketing trick"

The Anthropic DOD incident reflects dangerous corporate overreach, with private companies attempting to influence foreign policy beyond their legitimate scope

Photonic Computing: The Trillion-Dollar Hardware Revolution

Light naturally performs matrix multiplication through diffraction, offering potential 1000x performance improvement over current GPU architectures at the speed of light

The optical computing market represents "$5 to $10 trillion market cap up for grabs" with surprisingly few startups competing compared to thousands of AI agent companies

Key technical challenges include achieving nonlinearity in optical systems and creating optical memory, which Shkreli's startup believes they've solved

"I don't want to have data centers in space. I don't want to have nuclear reactors in my backyard. It'd be a lot easier if we just made a freaking better computer" - Martin on the need for hardware innovation

Success requires staying "in all optics" since electric-to-optical conversions eliminate performance advantages, with 100x minimum improvement needed to justify development

Big Tech's Shifting Competitive Landscape

Meta emerges as the strongest positioned company due to Zuckerberg's distribution advantage and product expertise, requiring only basic AI capabilities for most user queries

Apple appears most vulnerable among Mag 7 companies, having lost its innovative edge: "Apple was dangerous 20 years ago. It was new and Nouveau. It's kind of whatever now"

Google's Gemini struggles reflect deeper cultural issues, making the company feel "like Yahoo in 2000" despite having distribution advantages

Historical precedent suggests major disruption ahead: "you wouldn't recognize most of the Dow 30 from 100 years ago... half these companies are going to disappear"

Software Resilience in the AI Era

Complex B2B software like Bloomberg terminals remain defensible because "bond prices when he looks up a bond to be right" - accuracy and relationships matter more than AI generation

Financial software requires 1800+ news relationships versus the five sources typical AI applications provide, with traders caring about "the 1713th news source that's going to screw up his portfolio"

AI coding assistance enhances but doesn't replace core business requirements: "it doesn't replace marketing and sales. It doesn't replace product and taste. It doesn't replace personal relationships"

The Peptide Medicine Delusion

BPC-157, the flagship peptide drug, is fundamentally ineffective due to minute-long half-lives: "by the time you inject it, it's dead... it doesn't have the time to do anything useful"

The peptide trend represents rebellion against traditional medicine rather than scientific advancement: "it's about rebellion... I don't want to pay Pfizer. I don't want to see my doctor"

Peptides historically represent "one of the lowest desired drug classes in pharma" due to their inherently short half-lives, with GLP-1s succeeding only through extensive chemical modifications

DIY medicine creates dangerous regulatory inconsistencies where unproven peptides are freely available while promising FDA-reviewed drugs for deadly diseases get rejected

Pharma's Future: Rare Diseases and Patent Cliffs

Rare disease development remains the most profitable pharma strategy, offering potential million-dollar-per-patient returns for conditions like Duchenne muscular dystrophy

GLP-1 drugs face inevitable patent expiration challenges, with Ozempic going generic "in like a year or two" despite current trillion-dollar market caps

Warren Buffett rejected pharma investments because "we have to recreate our business every 10 years. Drug goes generic. I have to go find another one"

AI could revolutionize drug discovery through idea generation: "Fundamentally, the drug game is an idea game... AI can actually zip through thousands of ideas and come up with something"

Neuralink represents the pharma model applied to medical devices, potentially becoming "a hundred billion dollar plus, maybe even $200 billion company" by delivering million-dollar-per-patient productivity gains

SBF's Redemption Path and the Trust Problem

The $400 million Anthropic investment was a clear warning sign of customer fund misuse: "richest guys in the world don't just drop 400 million on a single deal"

SBF's redemption requires showing genuine humanity and vulnerability: "you have to show a scar or wound or bleed a little bit" rather than maintaining intellectual detachment

His MIT-to-Jane Street trajectory may have prevented normal human development: "he maybe didn't have the time to like be a normal person"

Despite legal troubles, serious investors are already "lined up for Sam's next thing" with "staggering" funding commitments in the hundreds of millions or billions